The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease

Contemporary Clinical Trials

Volumn 36, Issue 1, 2013, Pages 256-262

  Hooper, Megan ^a   Grill, Joshua D ^b   Rodriguez Agudelo, Yaneth ^c   Medina, Luis D ^b,d   Fox, Michelle ^b   Alvarez Retuerto, Ana Isabel ^b   Wharton, David ^b   Brook, Jenny ^b   Ringman, John M ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FAD; Genetic; Pre symptomatic; Prevention; Testing; Trials

Indexed keywords

PLACEBO;

ADULT; ALZHEIMER DISEASE; ARTICLE; ATTITUDE TO HEALTH; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; FEMALE; GENETIC RISK; GENETIC SCREENING; HUMAN; MALE; MEXICO; NEUROSURGERY; UNITED STATES;

AD; ALZHEIMER DISEASE; EARLY-ONSET FAMILIAL ALZHEIMER'S DISEASE; FAD; FRONTOTEMPORAL DEMENTIA; FTD; GENETIC; HD; HUNTINGTON DISEASE; PRE-SYMPTOMATIC; PREVENTION; TESTING; TRIALS;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MEXICAN AMERICANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRESENILIN-1; PRESENILIN-2; RESEARCH SUBJECTS; UNITED STATES;

EID: 84882804053     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.07.006     Document Type: Article

References (16)

1. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366(9503):2112-2117.
2. Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54(11 Suppl. 5):S10-S15.
3. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367(9):795-804.
4. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88(9):1337-1342.
5. Meinert C.L., McCaffrey L.D., Breitner J.C. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimers Dement 2009, 5(2):93-104.
6. Murrell J., Ghetti B., Cochran E., Macias-Islas M.A., Medina L., Varpetian A., et al. The A431E mutation in PSEN1 causing Familial Alzheimer's Disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 2006, 7(4):277-279.
7. Thal L.J. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20(3 Suppl. 2):S97-S99.
8. Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M., et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999, 65(3):664-670.
9. Fox N.C., Kennedy A.M., Harvey R.J., Lantos P.L., Roques P.K., Collinge J., et al. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 1997, 120(Pt 3):491-501.
10. Williamson J., LaRusse S. Genetics and genetic counseling: recommendations for Alzheimer's disease, frontotemporal dementia, and Creutzfeldt-Jakob disease. Curr Neurol Neurosci Rep 2004, 4(5):351-357.
11. Ringman J.M., Grill J., Rodriguez-Agudelo Y., Chavez M., Xiong C. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges. Alzheimers Dement 2009, 5(2):166-171.
12. Steinbart E.J., Smith C.O., Poorkaj P., Bird T.D. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001, 58(11):1828-1831.
13. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997, 9(Suppl. 1):173-176. [discussion 177-178].
14. Koehly L.M., Peterson S.K., Watts B.G., Kempf K.K., Vernon S.W., Gritz E.R. A social network analysis of communication about hereditary nonpolyposis colorectal cancer genetic testing and family functioning. Cancer Epidemiol Biomarkers Prev 2003, 12(4):304-313.
15. Reiman E.M., Langbaum J.B., Fleisher A.S., Caselli R.J., Chen K., Ayutyanont N., et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011, 26(Suppl. 3):321-329.
16. Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011, 2(6):35.